COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,900 Articles (22,568 medRxiv, 8,332 bioRxiv)

Most recent first Previous |  Page 1563: Articles 15621-15630  | Next

Multidose evaluation of 6,710 drug repurposing library identifies potent SARS-CoV-2 infection inhibitors In Vitro and In Vivo.
Patten, J., Keiser, P. T., Gysi, D. M., Menichetti, G., Mori, H., Donahue, C. J., Gan, X., do Valle, I. F., Geoghegan-Barek, K., Anantpadma, M., Berrigan, J. L., Jalloh, S. C., Ayazika, K. T., Wagner, F., Zitnik, M., Ayehunie, S., Anderson, D., Loscalzo, J., Gummuluru, S., Namchuk, M. N., Barabasi, A.-L., Davey, R. A.
10.1101/2021.04.20.440626 — Posted: 2021-04-20
Sentinel cells enable genetic detection of SARS-CoV-2 Spike protein
Weinberg, Z. Y., Hilburger, C. E., Kim, M., Cao, L., Khalid, M. M., Elmes, S., Diwanji, D., Hernandez, E., Lopez, J., Schaefer, K., Smith, A. M., Zhou, F., QCRG Structural Biology Consortium, , Kumar, G. R., Ott, M., Baker, D., El-Samad, H.
10.1101/2021.04.20.440678 — Posted: 2021-04-20
Identification of clinical features associated with mortality in COVID-19 patients
Eskandarian, R., Alizadeh Sani, Z., Behjati, M., Zahmatkesh, M., Haddadi, A., Kakhi, K., Roshanzamir, M., Shoeibi, A., Alizadehsani, R., Hussain, S., Khozeimeh, F., Keyvani, V., Khosravi, A., Nahavandi, S., Mohammed Shariful Islam, S.
10.1101/2021.04.19.21255715 — Posted: 2021-04-20
Study Pre-protocol for 'BronchStart - The Impact of the COVID-19 Pandemic on the Timing, Age and Severity of Respiratory Syncytial Virus (RSV) Emergency Presentations; a Multi-Centre Prospective Observational Cohort Study'
Williams, T. C., Lyttle, M. D., Cunningham, S., Sinha, I., Swann, O., Maxwell-Hodkinson, A., Roland, D., Paediatric Emergency Research in the UK and Ireland (PERUKI)
10.1101/2021.04.18.21255700 — Posted: 2021-04-20
Simulation of aerosol and droplet spread during upper airway and gastrointestinal endoscopy
Heymer, J., Dengler, F., Krohn, A., Jaki, C., Schilling, T., Mueller-Schilling, M., Kandulski, A., Ott, M.
10.1101/2021.04.20.21255743 — Posted: 2021-04-20
Emergence of the novel SARS-CoV-2 lineage P.4.1 and massive spread of P.2 in South Brazil
Sant'Anna, F. H., Varela, A. P. M., Prichula, J., Comerlato, J., Comerlato, C. B., Roglio, V. S., Pereira, G. F. M., Moreno, F., Seixas, A., Wendland, E. M.
10.1101/2021.04.14.21255429 — Posted: 2021-04-20
Inactivation of SARS-CoV-2 in chlorinated swimming pool water
Brown, J. C., Blackwell, A., Moshe, M., Barclay, W. S.
10.1101/2021.04.19.440446 — Posted: 2021-04-20
Comparison of Mucosal and Intramuscular Immunization against SARS-CoV-2 with Replication-Defective and Replicating Single-cycle Adenovirus Vaccines
Barry, M. A., Mudrick, H., McGlinch, E., Parrett, B., Hemsath, J., Barry, M., Rubin, J., Uzendu, C., Hansen, M., Erskine, C., VanKeulen, V., Drelich, A., Tseng, C.-T. K., Massey, C. S., Fida, M., Suh, G. A., Peikert, T., Block, M., Olivier, G.
10.1101/2021.04.20.440651 — Posted: 2021-04-20
Drug repurposing to face Covid-19: Celastrol, a potential leading drug capable of inhibiting SARS-CoV-2 replication and induced inflammation
Fuzo, C. A., Martins, R. B., Fraga-Silva, T. F. C., Amstalden, M. K., Canassa-DeLeo, T., Souza, J. P., Lima, T. M., Faccioli, L. H., Franca, S. C., Bonato, V. L. D., Neto, E. A., Dias-Baruffi, M.
10.1101/2021.04.20.439992 — Posted: 2021-04-20
Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants
Li, T., Han, X., Gu, C., Guo, H., Zhang, H., Wang, Y., Hu, C., Wang, K., Liu, F., Luo, F., Zhang, Y., Hu, J., wang, W., Li, S., Hao, Y., Shen, M., Huang, J., Long, Y., Song, S., Wu, R., Mu, S., Chen, Q., Gao, F., Wang, J., Long, S., Li, L., Wu, Y., Gao, Y., Xu, W., Cai, X., Qu, D., Zhang, Z., Zhang, H., Li, N., Gao, Q., Zhang, g., He, C., Wang, W., Ji, X., Tang, N., Yuan, Z., Xie, Y., Zhang, B., Yang, H., Huang, A., Jin, A.
10.1101/2021.04.19.440481 — Posted: 2021-04-20

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).